A coalition of health care providers, insurers, seniors and others is pushing back on some of the latest claims by the Pharmaceutical Research and Manufacturers of America that incorrectly blame hospitals for the rising price of drugs. The latest installment of the Campaign for Sustainable Rx Pricing鈥檚 鈥淪econd Opinion鈥 highlights how hospitals are subject to fixed reimbursements for the vast majority of care they provide, and the 鈥渢rue driver behind the rising costs is PhRMA鈥檚 willingness to do anything for an extra dollar, even if it means forcing patients to choose between paying for the medicines they need and their daily life necessities.鈥 CSRxP, of which the AHA is a founding member, said it will continue to fact check PhRMA鈥檚 false claims and move forward with patient-focused solutions to increase transparency, promote competition and ensure a drug鈥檚 price is based on how well it works for patients. 
 

Related News Articles

Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and鈥
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District鈥
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that鈥
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will鈥
Headline
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by鈥